Exelixis announced that The New England Journal of Medicine published results from the Celestial Phase 3 pivotal trial of cabozantinib in patients with previously treated advanced hepatocellular carcinoma.1 The data, originally presented at the 2018 American Society of Clinical Oncology’s Gastrointestinal Cancers Symposium in January, demonstrate that cabozantinib provided a statistically significant and clinically meaningful improvement in overall survival versus placebo, the company said in a statement. Median overall survival in Celestial was 10.2 months with cabozantinib versus 8.0 months with placebo. Median progression-free survival was more than doubled, at 5.2 months with cabozantinib and 1.9 months with placebo. “Patients with this form of advanced liver cancer have very limited treatment options once their disease progresses following treatment with sorafenib,” said Ghassan K. Abou-Alfa, M.D., Memorial Sloan Kettering Cancer Center, New York and lead investigator on Celestial. “These results suggest that, if approved, cabozantinib could become an important addition to the treatment landscape that may help slow disease progression and, critically, improve survival for these patients.”
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.